FDX1 Antibody - #DF7950

(4)   (2)  
Product: FDX1 Antibody
Catalog: DF7950
Description: Rabbit polyclonal antibody to FDX1
Application: WB IF/ICC
Cited expt.: WB
Reactivity: Human
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 19 kDa; 19kD(Calculated).
Uniprot: P10109
RRID: AB_2841351

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IF/ICC 1:200-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human
Prediction:
Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
FDX1 Antibody detects endogenous levels of total FDX1.
RRID:
AB_2841351
Cite Format: Affinity Biosciences Cat# DF7950, RRID:AB_2841351.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Adrenal ferredoxin; Adrenodoxin; Adrenodoxin, mitochondrial; ADX; ADX_HUMAN; FDX; fdx1; Ferredoxin 1; Ferredoxin-1; Hepatoredoxin; LOH11CR1D; Mitochondrial adrenodoxin; mitochondrial;

Immunogens

Immunogen:

A synthesized peptide derived from human FDX1, corresponding to a region within the internal amino acids.

Uniprot:

P10109(ADX_HUMAN) >>Visit HPA database.

Gene(ID):
FDX1(2230)
Expression:
P10109 ADX_HUMAN:

Highest levels in the adrenal gland (at protein level). Also detected in kidney and testis (at protein level).

Sequence:
MAAAGGARLLRAASAVLGGPAGRWLHHAGSRAGSSGLLRNRGPGGSAEASRSLSVSARARSSSEDKITVHFINRDGETLTTKGKVGDSLLDVVVENNLDIDGFGACEGTLACSTCHLIFEDHIYEKLDAITDEENDMLDLAYGLTDRSRLGCQICLTKSMDNMTVRVPETVADARQSIDVGKTS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Xenopus
100
Zebrafish
100
Chicken
100
Rabbit
100
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Essential for the synthesis of various steroid hormones. Participates in the reduction of mitochondrial cytochrome P450 for steroidogenesis. Transfers electrons from adrenodoxin reductase to CYP11A1, a cytochrome P450 that catalyzes cholesterol side-chain cleavage. Does not form a ternary complex with adrenodoxin reductase and CYP11A1 but shuttles between the two enzymes to transfer electrons (By similarity).

Subcellular Location:

Mitochondrion matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highest levels in the adrenal gland (at protein level). Also detected in kidney and testis (at protein level).

Family&Domains:

Belongs to the adrenodoxin/putidaredoxin family.

References

1). Photodynamic-Photothermal Switching in Osmium-Ferritin Nanoplatform Activates Near Infrared-Driven Tumor Immunity Reprogramming. ACS Nano, 2025 [IF=16.0]
2). Multifunctional drug delivery nanoparticles for combined chemotherapy/chemodynamic/photothermal therapy against colorectal cancer through synergistic cuproptosis/ferroptosis/apoptosis. Materials today. Bio, 2024 (PubMed: 39850244) [IF=8.7]
3). The signature genes of cuproptosis associates with tumor immune microenvironment and predicts prognosis in kidney renal clear cell carcinoma. Frontiers in oncology, 2024 (PubMed: 39206152) [IF=3.5]

Application: WB    Species: human    Sample: Caki-1 cells

Figure 5. Effect of Elesclomol on proliferation and migration of KIRC cells and regulation of FDX1. (A). Caki-1 cells viability was measured using the CCK-8 kit after treating with Elesclomol for 24, 48,72h. (B). EdU staining of Caki-1 cells. Scale bar, 200 μm; n=3; (C). Caki-1 cell EdU flourescence intensity analysis by flow cytometry. (D). The healing/closing state of Caki-1cells by the scratch assay (representative pictures from 3 repeated experiments). (E, F). FDX1 mRNA (E) and protein (F) expression level of Caki-1 cells treated with Elesclomol (500nM) for 48h. (G). The content of Fe-S cluster was tested of Caki-1 cells c treated with Elesclomol (500nM) for 48h. Experiments were repeated three times and the data are expressed as the mean ± SEM. *P < 0.05, ** P
4). Taxifolin regulates SLC31A1-mediated cuproptosis and tumor progression in hepatocellular carcinoma. Human cell, 2025 (PubMed: 39752031) [IF=3.4]

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.